Table 6.
Experimental design and summary of study treatment groups
| Group | Treatment | Dosage (mg/kg), Regimen, Route | CBPP Infection Kenya (VSRI)/Zambia (CVRI) |
Number of Animals Kenya (VSRI)/Zambia (CVRI)a | Intubation | Start of In-Contact Exposure Kenya (VSRI)/Zambia (CVRI) |
Treatment Administration Kenya (VSRI)/ Zambia (CVRI) |
Observation Period Kenya (VSRI)/Zambia (CVRI) |
|---|---|---|---|---|---|---|---|---|
| 0 | None | n/a |
Intubation with Afadé/Caprivi strain |
60/50 | Day 0 | 8/11 days after intubation | n/a | 49/49 days after intubation |
| 1 | Saline |
6.0 mg/kg Once SC |
In-contact with Group 0 | 15/13 (15) | n/a | 8/11 days after intubation | 41/38 days after start of in-contact exposure | 92/73 days after treatment |
| 2 | Tulathromycin |
2.5 mg/kg Once SC |
In-contact with Group 0 | 15/13 (15) | n/a | 8/11 days after intubation | 41/38 days after start of in-contact exposure | 92/73 days after treatment |
| 3 | Gamithromycin |
6.0 mg/kg Once SC |
In-contact with Group 0 | 15/13 (15) | n/a | 8/11 days after intubation | 41/38 days after start of in-contact exposure | 92/73 days after treatment |
| 4 | Oxytetracycline |
20.0 mg/kg Once IM |
In-contact with Group 0 | 15/14 (15) | n/a | 8/11 days after intubation | 41/38 days after start of in-contact exposure | 92/73 days after treatment |
| 5 | None | n/a | In-contact with Groups 1–4 | 20/18 (20) | n/a | 32/28 days after treatment (Groups 1 to 4) | n/a | 60/45 days after co-mingling |
aNumbers in brackets indicate the number of animals originally included into the study at CVRI: Seven animals from the combined group were withdrawn for welfare reasons unrelated to CBPP, before the start of the treatment phase and one sentinel was withdrawn before and one after co-mingling for welfare reasons unrelated to CBPP